Organization · Corporate Venture Capital
Ajinomoto Corporate Venture Capital
Ajinomoto Group Ventures (AGV) is the corporate venture capital arm of Ajinomoto Co., Inc., focusing on investments in global startups within healthcare, ICT, food and wellness, and green technology. Established in 2020, AGV operates from offices in Burlingame, Tokyo, and Palo Alto.
Overview
What Ajinomoto Corporate Venture Capital does
What Ajinomoto Corporate Venture Capital is
Ajinomoto Group Ventures (AGV) is the corporate venture capital arm of Ajinomoto Co., Inc., focusing on investments in global startups within healthcare, ICT, food and wellness, and green technology. Established in 2020, AGV operates from offices in Burlingame, Tokyo, and Palo Alto.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Corporate Venture Capital
- Founded
- Founded in 2020
- Approximate age
- About 6 years
- Structured capabilities
- Funder
- Last reviewed
- May 4, 2026
Official channels
Find Ajinomoto Corporate Venture Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Ajinomoto Corporate Venture Capital as a funder
Investment thesis
Ajinomoto Group Ventures invests in transformative companies that advance health, improve information processing, and address sustainability challenges, leveraging its expertise in amino acids and fermentation.
Focus narrative
AGV targets investments primarily in early-stage companies, particularly in Series A rounds, across sectors such as healthcare (including gene therapy and regenerative medicine), ICT (optics and advanced materials), food & wellness, and green technologies (fermentation and agrifood sustainability). The fund emphasizes strategic partnerships and co-investments with institutional VCs.
Value beyond capital
AGV provides strategic value to its portfolio companies by leveraging Ajinomoto's extensive expertise in amino acids, fermentation, and food science, as well as its global distribution networks and supply chains. This synergy enhances the potential for innovation and market success for its investments.
Focus and fit
- Stages
- Seed · Series A
- Regions
- Global · North America · Asia · Emea
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded notable exits
- Nubis
Portfolio context
Notable portfolio companies include: Fermeate: An optogenetic fermentation platform for sustainable biomanufacturing. Restore Vision: Developing optogenetic gene therapies for blindness. Mixx Tech: Specializes in optical integration for AI, having raised $33M in Series A funding. Cellular Intelligence: Uses AI to decode cellular biology and extend human health-span. Lasagna.one: Focuses on next-generation high-voltage solid-state batteries.
Common questions
What to know about Ajinomoto Corporate Venture Capital
Upseed classifies Ajinomoto Corporate Venture Capital under the Corporate Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 4, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.